Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
305-311
Author(s):
David Fernandez, Eduardo Bonilla, Paul Phillips and Andras Perl
Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
313-321
Author(s):
Volker Vielhauer and Hans-Joachim Anders
Type I Interferon as a Target of Treatment in SLE
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
323-330
Author(s):
P. Y. Lee and W. H. Reeves
Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
331-343
Author(s):
G. Munuswamy-Ramanujam, K. A. Khan and A. R. Lucas
Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
345-350
Author(s):
Robert Eisenberg
Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
351-358
Author(s):
William Stohl
NF-κ B and Rheumatic Diseases
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
359-372
Author(s):
Takashi Okamoto
Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
373-381
Author(s):
Hideko Nakahara and Norihiro Nishimoto
Role of PGE2 and EP Receptors in the Pathogenesis of Rheumatoid Arthritis and as a Novel Therapeutic Strategy
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
383-394
Author(s):
Jun Akaogi, Toshiko Nozaki, Minoru Satoh and Hidehiro Yamada
Targeting Fibrosis in Systemic Sclerosis
Journal:
Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume:
6
Page:
395-400
Author(s):
Robert Lafyatis